In order to investigate mechanisms underlying the ovarian steroid action on hypothalamic luteinizing hormone-releasing hormone (LHRH) neurons, LHRH and a higher immunoreactive molecular form (MW 1,800 daltons) of the decapeptide were immunoassayed with antibodies of different specificities in hypothalamic subcellular fractions, after molecular sieve filtration on Biogel P4 columns equilibrated with 0.2 N acetic acid containing 0.02% sodium azide. The study was performed in ovariectomized (OVX), ovariectomized estradiol-implanted (OVX + E2) or OVX -l- E2 progesterone-treated rats (OVX + E2 + P). The animals were killed before or during the circadian luteinizing hormone (LH) surge. The amount of LHRH-like immunoreactivity recovered from the synaptosomal fraction was slightly increased in OVX + E2-implanted animals but very markedly augmented in OVX + E2 + P-treated rats. In contrast, the higher molecular form recovered from a high-speed supernatant was markedly decreased in OVX + E2 + P-treated rats when compared to the other groups. At the time of maximal LH release induced by E2 + P administration, hypothalamic LHRH was markedly depleted, whereas the larger molecular form was notably augmented. The data suggest that ovarian steroids not only influence release of hypothalamic LHRH but also the processing of LHRH precursor forms.

Keywords:
17β-Estradiol, Progesterone, Luteinizing hormone-releasing hormone, native and precursor form
This content is only available via PDF.
© 1986 S. Karger AG, Basel
1986
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.